Jonathon B Cohen, Nirav N Shah, Alvaro J Alencar, James N Gerson, Manish R Patel, Bita Fakhri, Wojciech Jurczak, Xuan Ni Tan, Katharine L Lewis, Timothy Fenske, Catherine C Coombs, Ian W Flinn, David J Lewis, Steven Le Gouill, M Lia Palomba, Jennifer A Woyach, John M Pagel, Nicole Lamanna, Minal A Barve, Paolo Ghia, Toby A Eyre, Pier Luigi Zinzani, Chaitra S Ujjani, Youngil Koh, Koji Izutsu, Ewa Lech-Maranda, Constantine S Tam, Suchitra Sundaram, Ming Yin, Binoj Nair, Donald E Tsai, Minna Balbas, Anthony R Mato, Chan Y Cheah, Michael L Wang
CONTEXT: Covalent BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL), but most patients will require additional treatment. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi that inhibits both wild-type and C481-mutated BTK with equal low nM potency. OBJECTIVE: To evaluate pirtobrutinib safety and efficacy in patients with MCL. DESIGN: BRUIN is an ongoing multicenter phase 1/2 study (NCT03740529) of pirtobrutinib monotherapy...
October 2022: Clinical Lymphoma, Myeloma & Leukemia